Advertisement

Search Results

Advertisement



Your search for ,WhO matches 21072 pages

Showing 1651 - 1700


breast cancer

ESR1-Mutated Metastatic Breast Cancer

This is Part 1 of Next-Generation Therapies for Metastatic HR-Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri discuss the...

global cancer care

Making a Difference in Global Oncology

“Making a difference in global oncology means framing positive system changes. To me, Dr. Khalid El Bairi is among the global cancer researchers I know who so far has made the largest achievements. “Since the very first interaction with Khalid, what I have captured is passion for the community he...

global cancer care

Cancer Research and Care Beyond Borders for Global Oncologist Dario Trapani, MD

In this installment of The ASCO Post’s Living a Full Life series, I interviewed Dario Trapani, MD, a medical oncologist at the European Institute of Oncology, Milan and Assistant Professor at the Department of Oncology and Haemato-Oncology of the University of Milan, in Italy. Dr. Trapani is a...

skin cancer
immunotherapy

Key Immune Cells for Combating Aggressive Merkel Cell Carcinoma Uncovered

Researchers may have uncovered why some patients with Merkel cell carcinoma do not respond to immune checkpoint blockade therapy, according to a recent study published by Reinstein et al in Cancer Discovery. Background Merkel cell carcinoma—a rare but highly aggressive type of skin cancer—is known...

gastroesophageal cancer
hepatobiliary cancer
immunotherapy
issues in oncology

Fecal Microbiota Transplant May Help Patients With Gastrointestinal Cancers Overcome Immunotherapy Resistance

Fecal microbiota transplants may improve the effectiveness of immunotherapy in patients with gastrointestinal cancers, according to a recent study published by Kim et al in Cell Host & Microbe. Background Although immune checkpoint inhibitors have revolutionized cancer treatment, many patients...

hematologic malignancies
supportive care

Effect of Posttransplantation Cyclophosphamide-Based GVHD Prophylaxis on Patients With Hematologic Malignancies

In an analysis reported in the Journal of Clinical Oncology, Shaffer et al found that use of post–allogeneic hematopoietic cell transplantation (HCT) cyclophosphamide (PTCy)-based graft-vs-host disease (GVHD) prophylaxis resulted in comparable overall survival and GVHD-free, relapse-free survival...

leukemia

MRD-Negative ALL: Addition of Blinatumomab to Consolidation Chemotherapy

In the phase III ECOG-ACRIN E1910 trial reported in The New England Journal of Medicine, Mark R. Litzow, MD, and colleagues found that the addition of blinatumomab to consolidation chemotherapy improved overall survival among adult patients with BCR-ABL fusion–negative B-cell precursor acute...

prostate cancer

Baseline Bone Pain and Survival in Newly Diagnosed Prostate Cancer

In an analysis from the SWOG-1216 trial reported in JAMA Network Open, Gebrael et al found that the presence of bone pain at diagnosis was associated with poorer progression-free and overall survival in patients with newly diagnosed metastatic hormone-sensitive prostate cancer. Study Details In the ...

colorectal cancer

Guardant Health’s Shield Blood Test Approved by the FDA as a Primary Screening Option for Colorectal Cancer

On July 29, the U.S. Food and Drug Administration (FDA) approved Guardant Health’s Shield blood test for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. It is the first blood test to be approved by the FDA as a primary screening option for...

prostate cancer
issues in oncology

Is Lower-Dose Radiopharmaceutical Therapy Effective in Advanced Prostate Cancer?

Treatment with de-escalated actinium (Ac)-225–prostate-specific membrane antigen (PSMA)-617 or a combination of lutetium (Lu)-177/Ac-225–PSMA-617 resulted in similar median overall survival and prostate-specific antigen (PSA) response rates and better tolerance among patients with advanced-stage...

breast cancer
gynecologic cancers
issues in oncology

Risk of Breast Cancer May Be Lower Within First 10 Years Following Ovarian Cancer Diagnosis

Patients with BRCA1- or BRCA2-mutated ovarian cancer may have a lower risk of developing breast cancer following treatment, according to a recent study published by Evans et al in Genetics in Medicine. Background Previous research has estimated that the risk of developing breast cancer by the age...

breast cancer

Does Bilateral Mastectomy for Unilateral Breast Cancer Impact Mortality?

The results of a contemporary U.S. population–based cohort study published by Giannakeas et al in JAMA Oncology revealed that patients with unilateral breast cancer had an increased risk of breast cancer–related death after developing contralateral disease. Although the findings also showed a...

prostate cancer
cardio-oncology

Patients With Prostate Cancer: Social Factors May Be Tied to Racial Disparities in Cardiovascular Outcomes

Based on the results of a retrospective cohort study published by Demissei et al in JACC: CardioOncology, Black patients with prostate cancer who received systemic androgen-deprivation therapy (ADT) seemed to have a significantly greater likelihood of experiencing adverse cardiovascular disease...

breast cancer
supportive care

Update on Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial in Patients With Breast Cancer

Guest Editor’s Note: Chemotherapy and its side effects can lead to decreased physical activity and poor diet quality, resulting in unfavorable changes in physical functioning and quality of life. However, adopting healthy behaviors during cancer treatments can be challenging because of physical,...

solid tumors

Triplet as Initial Salvage Treatment for Advanced Germ Cell Tumors: Long-Term Outcomes

In a long-term analysis reported in the Journal of Clinical Oncology, Gleeson et al found that initial salvage treatment for germ cell tumors with paclitaxel, ifosfamide, and cisplatin (TIP) was associated with positive long-term outcomes in both favorable- and unfavorable-risk disease. Study...

cns cancers
issues in oncology

New Study Highlights Improvements in Treating Pediatric Patients With Retinoblastoma

The advancement of retinoblastoma treatment over the past 15 years may have resulted in a higher likelihood of vision preservation without compromising survival, according to a recent study presented by Kocharian et al at the Society of NeuroInterventional Surgery (SNIS) Annual Meeting 2024 and...

issues in oncology
hematologic malignancies
leukemia
lymphoma
bladder cancer

Cancer Risk From Exposure to Pesticides May Be Comparable to Risk From Smoking, Study Finds

Agricultural pesticides may carry a similar risk as smoking for some types of cancers, according to a recent study published by Gerken et al in Frontiers in Cancer Control and Society.   Background In modern agriculture practices, pesticides are essential to ensure high enough crop yields and food...

hepatobiliary cancer

Advanced Cholangiocarcinoma

This is Part 2 of Immunotherapy Strategies for Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Rachna T. Shroff, Nilo Azad, and Anthony B. El-Khoueiry discuss the management of advanced...

hepatobiliary cancer

Advanced Unresectable Hepatocellular Carcinoma

This is Part 1 of Immunotherapy Strategies for Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Rachna T. Shroff, Nilo Azad, and Anthony B. El-Khoueiry discuss the management of advanced unresectable...

Introducing ‘Conexiant’

The publisher and editorial staff of The ASCO Post are happy to share an exciting announcement. While our company was formerly known as Harborside, powered by BroadcastMed, earlier this summer we announced a new name and platform for our business, Conexiant. Importantly, we continue our essential...

lung cancer

Phase II Study Shows Activity for Novel Targeted Agent in KRAS G12C–Mutated NSCLC

The oral KRAS G12C inhibitor glecirasib has emerged as a therapeutic option for previously treated KRAS G12C–mutated non–small cell lung cancer (NSCLC). It may potentially improve efficacy and tolerability compared with current U.S. Food and Drug Administration–approved agents, according to data...

supportive care

Updated ASCO Guidance on Cancer-Related Fatigue Expands Patient Options for Interventions

A new update to the ASCO guideline on managing cancer-related fatigue recommends that health care providers urge their patients to exercise, as well as use cognitive-behavioral therapy and mindfulness-based programs to help prevent and treat this prevalent symptom.1 It is estimated that between 30% ...

lung cancer

Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations

On March 1, 2024, amivantamab-­vmjw (Rybrevant) was approved for use with ­carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and Drug Administration...

lymphoma

Triplet Combination Improves Survival in Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Third-Line Setting

The anti-CD30 antibody-drug conjugate brentuximab vedotin is a standard of care for certain types of lymphomas, including classical Hodgkin lymphoma in combination with multiagent chemotherapy. Brentuximab vedotin has also shown efficacy and safety in combination with lenalidomide and rituximab in...

issues in oncology

Failure to Diagnose and Statutes of Limitations: Lavern’s Law and Its Implications for Oncology

When health-care providers, including oncologists, fail to promptly diagnose a medical condition or communicate their diagnosis to their patients, it can have devastating consequences for those patients. In such cases, patients may seek legal recourse through medical malpractice lawsuits, creating...

colorectal cancer

Neoadjuvant Camrelizumab Plus Apatinib in Locally Advanced Colorectal Cancer

In a Chinese phase II study (NEOCAP) reported in The Lancet Oncology, Yu et al found that neoadjuvant camrelizumab plus apatinib produced promising complete response rates in patients with locally advanced microsatellite instability–high or mismatch repair–deficient colorectal cancer. Study ...

multiple myeloma
immunotherapy

Multiple Myeloma: Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy

A simple blood test that measures lymphocyte counts may predict whether patients with relapsed multiple myeloma are going to respond well to chimeric antigen receptor (CAR) T-cell immunotherapy, according to research published by Saldarriaga et al in Blood Advances. The study found that patients...

lymphoma
immunotherapy
issues in oncology

Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL

Two hallmark toxicities of chimeric antigen receptor (CAR) T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma (DLBCL), supporting a shorter, more flexible toxicity monitoring period., according to a recent study published by Ahmed et al in...

colorectal cancer
issues in oncology

Eliminating Racial Disparities in Colorectal Cancer Screening

Eliminating racial disparities in colorectal cancer testing may reduce the rate of colorectal cancer incidence and mortality among Black patients in the United States, according to a recent study published by Alagoz et al in the Journal of the National Cancer Institute. Background Although both the ...

hepatobiliary cancer
immunotherapy

Immunotherapy in Unresectable HCC With Child-Pugh Class B Dysfunction

In a retrospective study reported in JAMA Oncology, Fulgenzi et al found evidence that immune checkpoint inhibitor (ICI)-based treatment may improve survival vs best supportive care as first-line therapy in patients with unresectable hepatocellular carcinoma and Child-Pugh class B (CP-B) liver...

cardio-oncology

Does Neighborhood Walkability Impact the Burden of Cardiovascular Risk Factors in Patients With Cancer?

The results of a cross-sectional study reported in JACC: CardioOncology by Nwana et al revealed a significant association between the extent to which a neighborhood facilitates walking and the burden of modifiable cardiovascular risk factors among patients with a history of cancer. “[The findings...

solid tumors
issues in oncology

AACR, ASA, FDA Outline Considerations for Overall Survival Analyses in Clinical Trials

Experts from the American Association for Cancer Research (AACR), American Statistical Association (ASA), and U.S. Food and Drug Administration (FDA) have outlined considerations for clinical trial designs to enhance the collection and analysis of overall survival data in the context of modern-day...

prostate cancer
issues in oncology

Liquid Biopsy May Enable Monitoring of Disease Evolution in Patients With Metastatic Prostate Cancer

DNA/RNA material contained in circulating extracellular vesicles secreted into the blood stream by tumor cells may capture cancer genomics and transcriptomic evolution in patients with metastatic prostate cancer, according to a recent study published by Casanova et al in Cancer Cell. Background...

colorectal cancer
issues in oncology

Panel Issues First Guidelines to Prevent Anal Cancer in Patients With HIV

Researchers have introduced the first screening and treatment recommendations to prevent anal cancer in patients with the human immunodeficiency virus (HIV), according to new guidelines based on the results of a 2022 study published by Palefsky et al in The New England Journal of Medicine....

colorectal cancer
immunotherapy

pMMR/MSS Locally Advanced Rectal Cancer: Immunotherapy-Based Total Neoadjuvant Therapy

In a Chinese phase II trial (TORCH) reported in the Journal of Clinical Oncology, Xia et al found that integration of the PD-1 inhibitor toripalimab into total neoadjuvant therapy was associated with good outcomes in patients with mismatch repair–proficient or microsatellite-stable (pMMR/MSS)...

breast cancer
genomics/genetics

Early Breast Cancer: Genetic Testing and Communication of Results With Family After Diagnosis

In a U.S. study reported in the Journal of Clinical Oncology, Steven J. Katz, MD, MPH, and colleagues found that many women with early breast cancer and indications for genetic testing do not undergo said testing. Study Details    The study involved data from 1,412 women aged 20 to 79 years...

issues in oncology
survivorship

Preserving Reproductive Health for Patients With Cancer: Insights From an Oncofertility Patient Navigator

Advancements in cancer therapies have led to increased survival rates, but this progress has come with a cost: many life-saving treatments may impair fertility, leaving patients and cancer survivors grappling with the potential loss of their reproductive abilities. Oncofertility, a field that...

prostate cancer
genomics/genetics

Can Living in a Disadvantaged Area Increase the Risk of Aggressive Prostate Cancer?

Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, new research suggests, which in turn may contribute to higher rates of aggressive prostate cancer in African American men. These findings were published by Boyle et al in JAMA Network Open....

breast cancer
survivorship
genomics/genetics

Are Eligible Breast Cancer Survivors Receiving Genetic Testing?

Researchers have found that many eligible breast cancer survivors may not be receiving genetic counseling and testing, according to a recent study published by Katz et al in the Journal of Clinical Oncology. Background A growing proportion of cancer treatment and survivorship care relies on...

genomics/genetics
breast cancer
gynecologic cancers
colorectal cancer
solid tumors

Uncovering the Genetic Risk of Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome

Some patients with a genetic predisposition for cancer may not qualify for genetic screenings under the current guidelines, according to a recent study published by Samadder et al in JCO Precision Oncology. Researchers are investigating how to advance personalized medicine and tailor prevention and ...

immunotherapy

Immunotherapy-Induced Multiorgan Immune-Related Adverse Events: Co-occurrence Patterns and Prognostic Implications

The results of a retrospective multicohort study, reported in The Lancet Oncology by Wan et al, suggested that the identification of the immune-related adverse event cluster to which a patient belongs may aid in prognosticating response to immunotherapy. “These insights can be leveraged to counsel...

breast cancer
genomics/genetics

New Genetic Test May Predict Response to Immunotherapy in Triple-Negative Breast Cancer

The search for biomarkers of response to immunotherapy is high on the list of cancer-related research efforts. A new classifier in triple-negative breast cancer is showing promise and is currently being validated in the I-SPY2.2 trial, according to Laura van ’t Veer, PhD, Professor of Laboratory...

breast cancer
issues in oncology
supportive care

Testosterone Therapy May Protect Against Breast Cancer in Transmasculine Patients

Gender-affirming testosterone therapy may have a potential protective benefit in transmasculine patients at risk of breast cancer, according to a recent study published by Heng et al in Breast Cancer Research. Background To treat their gender dysphoria, some transmasculine patients undergo...

hematologic malignancies
issues in oncology

Donor Socioeconomic Status May Influence Outcomes in Hematopoietic Cell Transplantation

Investigators have demonstrated that the socioeconomic status of cell donors may impact the health outcomes of patients with hematologic malignancies who undergo hematopoietic cell transplantation, according to a recent study published by Turcotte et al in PNAS.  Study Methods and Results In the...

Neha Vapiwala, MD, FACR, FASTRO, FASCO, Voted President-Elect of ASTRO

The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ASTRO’s Board of Directors: Neha Vapiwala, MD, FACR, FASTRO, FASCO, President-Elect Jean Wright, MD, FASTRO, Clinical Affairs and Quality Council Vice Chair Andrea Ng, MD, MPH, FASTRO,...

breast cancer
geriatric oncology

Electronic Health Record–Based Prompt May Help Reduce Breast Cancer Overtreatment

Researchers have developed a novel prompt, embedded in electronic health records, to flag older patients with early-stage breast cancer who may be at risk of unnecessary sentinel lymph node biopsy, according to a recent study published by Carleton et al in JAMA Surgery.  Background “In breast...

colorectal cancer

Long-Term Survival Possible After Liver Transplant for Colorectal Liver Metastases

In selected patients with unresectable colorectal liver metastases, liver transplantation plus chemotherapy significantly boosted overall survival as compared with chemotherapy alone in the multicenter, European TRANSMET trial, presented at the 2024 ASCO Annual Meeting.1 The combined approach led...

breast cancer

A Role for Avelumab in Triple-Negative Breast Cancer?

In patients with triple-negative early breast cancer deemed to be at high risk for recurrence, 1 year of adjuvant avelumab did not significantly improve disease-free survival but did significantly improve overall survival and risk of distant disease–free survival events. The results from the...

hematologic malignancies
issues in oncology

New Study Demonstrates Safe, Successful Pregnancy May Be Possible Following Allo-HCT

Female patients may become pregnant and give birth to healthy children despite treatment-related fertility challenges following allogeneic hematopoietic cell transplantation (allo-HCT), according to a recent study published by Sockel et al in Blood. The findings highlighted the need for increased...

breast cancer
issues in oncology
supportive care

Hormone-Modulating Therapy May Be Linked to Lower Dementia Risk in Patients With Breast Cancer

Hormone-modulating therapy used to treat patients with breast cancer may be associated with a 7% lower risk of developing Alzheimer’s disease and related dementias later in life, according to a recent study published by Cai et al in JAMA Network Open. Background About 67% of patients with breast...

Advertisement

Advertisement




Advertisement